Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

Trial Profile

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2019

At a glance

  • Drugs Itolizumab (Primary) ; Corticosteroids
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EQUATE
  • Sponsors Equillium
  • Most Recent Events

    • 11 Mar 2019 Status changed from not yet recruiting to recruiting.
    • 26 Feb 2019 According to an Equillium media release, the company expects to initiate this trial by the end of the first quarter of 2019.
    • 02 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top